Stay updated on Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page
- Check6 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.0%

- Check13 days agoChange DetectedPublications section updated: two new articles added and one article removed.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed the lapse-in-government-funding notice and Revision: v3.4.1.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a Publications reference for Larkin et al. (Combined Nivolumab and Ipilimumab in untreated melanoma) replacing the older Larkin et al. NEJM citation, and a site-wide notice about government funding and NIH status was also added.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded glossary toggle label, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and revised the page version to v3.4.0 (from v3.3.4). These changes are limited to UI text and metadata and do not alter the study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Metastatic Cancer Clinical Trial page.